The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy

Documenti analoghi

• Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma
  di: Kazuya Kariyama, et al.
  Pubblicazione: (2026)
• Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
  di: Atsushi Naganuma, et al.
  Pubblicazione: (2025)
• Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab–Treated HCC
  di: Tomomitsu Matono, et al.
  Pubblicazione: (2025)
• Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab
  di: Kazunari Tanaka, et al.
  Pubblicazione: (2025)
• Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab
  di: Tomomitsu Matono, et al.
  Pubblicazione: (2025)